NO20002412L - Method of treating tumors and tumor cells using ex vivo activated T cells - Google Patents
Method of treating tumors and tumor cells using ex vivo activated T cellsInfo
- Publication number
- NO20002412L NO20002412L NO20002412A NO20002412A NO20002412L NO 20002412 L NO20002412 L NO 20002412L NO 20002412 A NO20002412 A NO 20002412A NO 20002412 A NO20002412 A NO 20002412A NO 20002412 L NO20002412 L NO 20002412L
- Authority
- NO
- Norway
- Prior art keywords
- cells
- treating tumors
- vivo activated
- tumor cells
- vivo
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 210000004881 tumor cell Anatomy 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000028993 immune response Effects 0.000 abstract 2
- 230000003211 malignant effect Effects 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Det er tilveiebrakt nye fremgangsmåter for modulering av en immunrespons ved anvendelse av behandling med T-celler som behandles ex vivo. Oppfinnelsen tilveiebringer en løsning på problemene som angår behandling av forskjellige sykdommer, spesielt sykdommer med malign beskaffenhet. Oppfinnelsen tilveie- bringer dessuten fremgangsmåter for behandling av sykdommer av ikke-malign beskaffenhet, ved modulering av et pattedyrs immunrespons.New methods have been provided for modulating an immune response using treatment with T cells treated ex vivo. The invention provides a solution to the problems related to the treatment of various diseases, especially diseases of a malignant nature. The invention further provides methods for treating diseases of non-malignant nature by modulating a mammalian immune response.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6503197P | 1997-11-10 | 1997-11-10 | |
PCT/US1998/023954 WO1999024045A1 (en) | 1997-11-10 | 1998-11-10 | Methods for treatment of tumors and tumor cells using ex vivo activated t cells |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20002412D0 NO20002412D0 (en) | 2000-05-09 |
NO20002412L true NO20002412L (en) | 2000-07-07 |
Family
ID=22059894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20002412A NO20002412L (en) | 1997-11-10 | 2000-05-09 | Method of treating tumors and tumor cells using ex vivo activated T cells |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1030674A1 (en) |
JP (1) | JP2001522806A (en) |
AU (1) | AU1395499A (en) |
CA (1) | CA2309206A1 (en) |
NO (1) | NO20002412L (en) |
WO (1) | WO1999024045A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7718196B2 (en) | 2001-07-02 | 2010-05-18 | The United States Of America, As Represented By The Department Of Health And Human Services | Rapamycin-resistant T cells and therapeutic uses thereof |
AU2003265948B8 (en) | 2002-09-06 | 2009-09-03 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
CA2525519A1 (en) * | 2003-05-08 | 2004-12-02 | Xcyte Therapies, Inc. | Generation and isolation of antigen-specific t cells |
US7435592B2 (en) | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
JP2007525225A (en) | 2004-02-26 | 2007-09-06 | イミュノバティブ セラピーズ, リミテッド | Method for preparing T cells for cell therapy |
US7592431B2 (en) | 2004-02-26 | 2009-09-22 | Immunovative Therapies, Ltd. | Biodegradable T-cell Activation device |
JP2010032444A (en) * | 2008-07-30 | 2010-02-12 | Olympus Corp | Living tissue treatment device |
CA2838046C (en) | 2011-05-03 | 2023-03-07 | Immunovative Therapies, Ltd. | Induction of il-12 using immunotherapy |
CN108261423B (en) | 2011-05-03 | 2021-01-08 | 免疫创新治疗有限公司 | Method for processing biological medicine containing living cells |
JP6994021B2 (en) | 2016-08-26 | 2022-01-14 | ジュノー セラピューティクス インコーポレイテッド | How to count the particles present in a cell composition |
PL3644728T3 (en) | 2017-06-28 | 2022-12-05 | Sci-Group As | Freezing of biological material |
EP3759490A1 (en) * | 2018-02-28 | 2021-01-06 | Juno Therapeutics, Inc. | Methods for detecting particles present in a cell composition |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE873057L (en) * | 1986-11-13 | 1988-05-13 | Tretorn Ab | Compositions and method for treatment of cancer using¹monoclonal antibody against gd3 ganglioside together eith¹il-2 |
EP1488805A2 (en) * | 1992-04-07 | 2004-12-22 | The Regents of the University of Michigan | CD28 pathway immunoregulation |
PT700430E (en) * | 1993-06-04 | 2005-07-29 | Univ Michigan | PROCESS FOR SELECTIVELY STIMULATING T-CELL PROLIFERATION |
WO1997005239A1 (en) * | 1995-07-25 | 1997-02-13 | Celltherapy, Inc. | Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease |
-
1998
- 1998-11-10 WO PCT/US1998/023954 patent/WO1999024045A1/en active Search and Examination
- 1998-11-10 JP JP2000520136A patent/JP2001522806A/en active Pending
- 1998-11-10 CA CA002309206A patent/CA2309206A1/en not_active Abandoned
- 1998-11-10 EP EP98957775A patent/EP1030674A1/en not_active Withdrawn
- 1998-11-10 AU AU13954/99A patent/AU1395499A/en not_active Abandoned
-
2000
- 2000-05-09 NO NO20002412A patent/NO20002412L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2309206A1 (en) | 1999-05-20 |
WO1999024045A1 (en) | 1999-05-20 |
NO20002412D0 (en) | 2000-05-09 |
AU1395499A (en) | 1999-05-31 |
JP2001522806A (en) | 2001-11-20 |
EP1030674A1 (en) | 2000-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20002412L (en) | Method of treating tumors and tumor cells using ex vivo activated T cells | |
DK0986382T3 (en) | RAF kinase inhibitors | |
NO974275L (en) | Method of treating tumors | |
DE69830072D1 (en) | RADIOACTIVE COMPOSITIONS FOR THE TREATMENT OF PROSTATE TUMORS | |
EA199800391A1 (en) | Inhibition of tumor growth by antisense oligonucleotides to IL-8 and IL-8 receptor | |
GB2344532A (en) | Electromagnetic radiation therapy | |
MY121548A (en) | Compounds and methods for the treatment of cancer | |
ATE378014T1 (en) | SYSTEM FOR TREATING ABNORMAL TISSUE IN THE HUMAN ESOPHAUS | |
EA200100573A1 (en) | APPLICATION OF CYCLOOXIGENASE-2 INHIBITOR, MATRIC METALLOPROTEINASE INHIBITOR, ANTI-TUMOR MEDICINE, AND OPTIONAL IRRADIATION AS A COMBINED METHOD OF TREATING THE NEO. | |
ATE260666T1 (en) | CELLULAR VACCINE AND USE THEREOF FOR THE TREATMENT OF MALIGNANT SOLID TUMORS | |
ATE258796T1 (en) | USE OF VITAMIN D4 DERIVATIVES TO TREAT SKIN DISEASES | |
ES2118414T3 (en) | USE OF INDOLOCARBAZOL DERIVATIVES FOR THE TREATMENT OF PROSTATE. | |
NO974824L (en) | Arteriovenous and venous transplant treatments, procedures and mixtures | |
DK0912192T3 (en) | Administration of GM-CSF to treat brain tumors and prevent the recurrence of such tumors | |
NO20000752L (en) | Method of preventing or treating estrogen-dependent diseases and disorders | |
ATE402713T1 (en) | GENETICALLY MANIPULATED HERPES VIRUSES FOR THE TREATMENT OF TUMORS | |
NO965395L (en) | Human monoclonal antibodies specific for cell cycle-independent glioma surface antigen | |
ES2187648T3 (en) | METHOD FOR THE ADMINISTRATION OF PHARMACOS FOR GENE THERAPY. | |
EA200300525A1 (en) | Glycosidation of indolcarbazole using interphase catalysis | |
ATE392210T1 (en) | METHODS OF TREATING SOLID TUMORS AND METASTASIS USING GENE THERAPY | |
DE60044350D1 (en) | PROSTATE SPECIFIC GEN PCGEM1 AND METHODS OF USE FOR THE RECOGNITION, TREATMENT AND PREVENTION OF PROSTATE CANCER | |
DE3856329D1 (en) | Use of Ethisterone for topical treatment of acne or androgenetic alopecia | |
ATE251462T1 (en) | METHOD FOR TREATING SCAR TISSUE | |
Karu et al. | Biological action of low-intensity monochromatic light in the visible range | |
GB9907048D0 (en) | Novel glucocorticoid receptor ligands for the treatment of meta bolic disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |